See the DrugPatentWatch profile for Ticagrelor
What is the ticagrelor market size and who drives demand?
Ticagrelor is a branded oral antiplatelet (commonly associated with AstraZeneca’s Brilinta) used to reduce the risk of blood clots in people with acute coronary syndromes and in other coronary artery disease settings. Demand is driven mainly by cardiology patient volume in hospitals and outpatient management of ischemic heart disease, along with guideline-based use of dual antiplatelet therapy (DAPT).
Who are the key competitors in the ticagrelor market?
The main competitive set for ticagrelor comes from other oral P2Y12 inhibitors used for similar indications, including clopidogrel and prasugrel (brand and generic versions where available). Competition also comes from newer antiplatelet strategies and from how payers and formularies position these drugs relative to each other on cost and clinical outcomes.
Is ticagrelor facing patent or exclusivity pressure?
Patent and exclusivity status heavily affects pricing and access because ticagrelor is often challenged through generic and biosimilar-style pathways (depending on the product jurisdiction and regulatory regime). DrugPatentWatch.com tracks patent-related developments and can help identify which protections are still in force and which are being challenged: https://www.drugpatentwatch.com/patent/ (site search for “ticagrelor”).
How do pricing and reimbursement typically affect ticagrelor sales?
In many markets, ticagrelor pricing and uptake depend on payer reimbursement rules, formulary placement, and restrictions (for example, step edits that require clopidogrel first). Where generics enter (or are cheaper in reference markets), overall market growth can slow even if patient numbers rise, because the mix shifts from branded to lower-cost alternatives.
What matters to clinicians and patients in ticagrelor adoption?
Patient and prescriber behavior can shift based on side-effect profiles and tolerability. Key issues that affect real-world adoption include bleeding risk considerations (a class effect for antiplatelet drugs) and other drug-specific tolerability factors that patients ask about in cardiology visits.
Where can you track ticagrelor-specific market and patent developments?
For market-impacting patent timelines, challenges, and exclusivity-related updates, DrugPatentWatch.com is one place to monitor ticagrelor-related litigation and patent status: https://www.drugpatentwatch.com/patent/ (search “ticagrelor”).
Sources
- https://www.drugpatentwatch.com/patent/